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Summary Murine monoclonal antibodies directed against tumour associated antigens are potentially useful in
tumour diagnosis and therapy. However, all the antigens they recognise may be heterogeneously expressed on
tumours and this may allow escape of cells from therapy if a single monoclonal antibody is used. One
approach is to use combinations of monoclonal antibodies recognising complementary cell surface antigens. A
flow cytometric method which allows accurate quantitation of the intensity of staining and the percentage of
fresh primary tumour cells binding a series of monoclonal antibodies has therefore been developed. This
allows calculations as the number of drug molecules which could be potentially delivered by each monoclonal
antibody and the optimal combination of antibodies which should be used. Monoclonal antibodies recognising
Y hapten (C14), CEA (228, 161) and 791T-p72 antigen (791T/36) have been screened as a possible combina-
tion for colorectal cancer. There was inter-tumour variation in the binding of all the monoclonal antibodies
although combinations could reduce or abrogate this problem. A combination of the monoclonal antibodies
C14, 228, 791T/36 and 161 would recognise 100% of tumours. Sixty per cent of tumours bound all four
antibodies, 78% any three, 90% any two and 100% any one antibody. There was also intra-tumour variation
in the number of tumour cells per lesion that were recognised, the best monoclonal antibody, 161, stained a
mean of 59% ofcells per tumour whereas the anti-cytokeratin monoclonal antibody stained a mean of 74% of
cells per tumour. An increased intensity of staining of tumour membranes was observed when a combination
of C14 and 228 was used compared to binding of individual antibodies. Furthermore there was still no
significant binding to normal colon membranes. Combinations of monoclonal antibodies which recognise a
high percentage of tumours are likely to be necessary for monoclonal antibody drug targeting to prevent
tumour recurrence and/or metastases.
A variety of monoclonal antibodies reactive with colorectal
tumour associated antigens have been described (Steplewski
et al., 1982; Herlyn et al., 1979; Lindholm et al., 1983;
Durrant et al., 1986a). However, one problem that needs to
be solved before monoclonal antibodies can be used
effectively for imaging or therapy is the heterogeneity of cell
surface antigen expression on tumours (Durrant et al., 1986a;
Brattain et al., 1981; Dexter et al., 1981). Variation in
antigen expression and density on individual tumour cells
from primary and metastatic tumours (Ballantyne et al.,
1986) could account in part for the difficulties in detecting all
known lesions in vivo using a single radiolabelled monoclonal
antibody and could lead to escape from the cytotoxic effects
of a single monoclonal antibody-drug conjugate. One app-
roach to these problems is to use a combination of mono
clonal antibodies which recognise distinct surface antigens
and/or epitopes covering the range of heterogeneous antigen
expression.
Although this is not a new concept very few studies have
been published showing that combinations of antibodies
recognise a larger number of primary tumours. Most studies
have used either cell lines or human xenografts, neither of
which has the heterogeneity observed in human tumours.
Our early studies (Durrant et al., 1986a) showed that it was
necessary to analyse at least 50 individual colorectal tumours
to obtain a clear picture of tumour phenotypes as the inter-
tumour variation was so diverse. In this report we compared
the binding of a panel of anti-colorectal monoclonal
antibodies reactive with different 'tumour associated' epitopes
singly and in combinations, to colorectal tumour cells.
The monoclonal antibodies have been selected because
they bind preferentially to tumour cells compared to a panel
of normal tissues as assayed by immunocytochemical staining
ofcryopreserved tissues. 791T/36 recognises a glycoprotein of
molecular weight 72,000 which is expressed on colorectal
osteosarcoma and ovarian tumours. Its main reactivity with
normal tissues is with activated T lymphocytes and stromal
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tissues (Embleton et al., 1981; Price et al., 1983a, b). It has
been used extensively for colorectal tumour imaging (Far-
rands et al., 1982; Armitage et al., 1983) and linked to ricin
A chain has been screened in a phase 1 clinical trial (Byers et
al., 1989). 228 recognises carcinoembryonic antigen and not
normal cross-reacting antigen. Its main normal reactivity is
with secretory components of the gastrointestinal tract. It has
also been shown to localise in tumours of colorectal cancer
patients (Pimm et al., 1986). 161 antibody also recognises
CEA but also cross-reacts with NCA. It therefore binds to a
number of normal tissues, including liver and kidney tissues
and would therefore be of limited clinical value. C14 recog-
nises the Y haptenic blood group antigen which is expressed
widely on colorectal cancers and adenomas (Lloyd et al.,
1983; Brown et al., 1984; Abe et al., 1986; Durrant et al.,
1986a, b; Ernst et al., 1986). Its main reactivity with normal
tissues is restricted to secretory epithelial tissues in individ-
uals who secrete blood group substances (Brown et al., 1984).
Although immunoperoxidase staining of tumour cells by
monoclonal antibodies was ideal for showing spatial relation-
ships between cells it could not quantitate cell surface expres-
sion and was extremely time consuming for calculating the
number of positive cells. A quantitative flow cytometric tech-
nique for rapid analysis of cell surface antigen expression on
cell suspensions from solid tumours has therefore been
developed. The relative binding of combinations of
antibodies as compared to single antibodies has also been
quantitatively compared by ELISA on tumour and normal
extranuclear membrane extracts.
Our results indicate that more colorectal cancers were
recognised and the intensity of staining was increased by
using combinations of monoclonal antibodies when com-
pared to a single antibody.
Materials and methods
Tumour cells
Cell suspensions were prepared from tissue of 50 individual
tumours within 18 h of removal. Tissue was finely minced
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and disaggregated in 0.05% collagenase (Boehringer, Mann-
heim, FR Germany) as previously described (Durrant et al.,
1986a). This collagenase had no effect on antigen expression
on cultured cell lines. The clinicopathology of these tumours
is shown in Table I.
Monoclonal antibodies
Antibodies to tumour associated antigens A panel of murine
monoclonal antibodies were used in this study. 791T/36 is an
IgG2b monoclonal antibody which recognises the 791T p72
antigen found in many carcinomas (Embleton et al., 1981;
Price et al., 1983). C14 is an IgM monoclonal antibody which
recognises the Y haptenic blood group antigen expressed by
the majority of colon adenocarcinomas (Brown et al., 1983).
161 is an IgG, monoclonal antibody that recognises a similar
epitope expressed on CEA and NCA (Price et al., 1987).
Finally, 228 monoclonal antibody recognised an epitope only
expressed on CEA (Price et al., 1987).
Antibodies to normal tissue components F15-42 reactive
with human Thy 1 antigen (McKenzie & Fabre, 1981) and
FIO-89-4 (Dalchau et al., 1980) reactive with human
leukocyte common antigen were obtained from Serotec Ltd
(Bicester, UK). These antibodies recognise stromal cells and
leukocytes respectively. Monoclonal antibody Cam 5.2
(Becton Dickinson, Oxnard, CA, USA) recognises
cytokeratin, a cytoskeletal component of all epithelial cells
(Makin et al., 1984).
Indirect immunofluorescence
Cells were washed twice in Hank's balanced salt solution
(HBSS) and stained by indirect immunofluorescence as
previously described (Durrant et al., 1986a, b). All the
monoclonal antibodies, singly and in combinations, were
used at 100 .tg ml-', 10 Lg per tube which has been shown to
be an excess of antibody by titration experiments on cells
expressing each antigen at high density. Cells staining with
Cam 5.2, which recognises an internal antigen, were pre-fixed
with paraformaldehyde (1%, 20 min). The analysis was
restricted to the size range of malignant cells by appropriate
forward angle scatter gating. Fluorescence intensity is ex-
pressed as a mean channel number (mean linear fluorescence,
MLF) calculated by multiplying the contents of each channel
by its channel number and dividing by the total number of
cells in the distribution. Each tumour and cell line was also
stained using normal mouse immunoglobulin and the MLF
in this control was subtracted from the values obtained with
monoclonal antibody. However, the MLF of binding of nor-
Table I Clinicopathology of colorectal tumours
Stagea Gradeb Site Ploidy
Disaggregated tumours
A 26% Vad. 4% Colon 42% A 52%
B 30% W 14% Rectum 58% D 48%
C 20% M 64%
D 24% P 18%
Tumour ENMpreparations
A 7% Vad. 0% Colon 58% A 42%
B 25% W 0% Rectum 42% D 58%
C 25% M 75%
D 33% p 25%
aDukes' staging with stage D describing tumours with distant metas-
tases. bVad., villous adenoma. The high percentage ofA tumours is due
to the active screening programme in Nottingham. W, well
differentiated; M, moderately differentiated; P, poorly differentiated.
cPloidy A, aneuploid tumours were stained with propidium iodide and
analysed flow cytometrically. Tumours were aneuploid if their DNA
index was between 1.1 and 1.9 and greater than 10% of the total cells
produced theabnormal GO/G1 peak orifthe indexwas between 1.9and
2.1 and greater than 15% ofthe total cellsproduced thesecond peak. D,
diploid.
mal mouse immunoglobulin was 58 ± 32 and therefore
tumours were only described as staining significantly if the
MLF exceeds 58 + two standard deviations, i.e. 122.3. This
was a conservative estimated as background levels with nor-
mal mouse immunoglobulin have already been subtracted.
The percentage of positively stained cells was calculated as
the number of cells with a fluorescence that exceeded the
value in which 95% of cells staining with normal mouse
immunoglobulin were observed.
Extranuclear membrane preparations
Fresh surgically resected colorectal adenocarcinomas or nor-
mal colonic mucosa were homogenised in a buffer containing
1 mM NaHCO3, 2 mM CaCl2, 2 mM MgC12, 1 mM
phenylmethylsulphonyl fluoride pH 7.6 (4 vol. of buffer per g
of tissue) to prepare a crude membrane preparation as des-
cribed previously (Brown et al., 1983). Membranes were
prepared from 12 individual tumours. The clinicopathology
of these tumours is shown in Table I.
Solidphase enzyme linked immunoadsorbent assay
Extranuclear membranes were diluted to 0.2 mg ml-' protein
in phosphate buffered saline (PBS) and 25 lI aliquots were
added per well in type 3912 polyvinylchloride (PV) microtitre
plates (Becton Dickinson, CA, USA). After an 18 h incuba-
tion at 4'C the wells were washed in PBS containing 0.05%
Tween 20 (washing buffer) and filled with PBS containing
1% BSA. After I h at 4°C the wells were emptied and
washed twice with washing buffer followed by addition of
25 tLI of hybridoma supernatant per well. After I h at room
temperature the wells were washed five times with washing
buffer and then 150 tlI of goat IgG anti-mouse Ig (Sigma,
Poole, UK) conjugated to alkaline phosphatase was added
for a further 1 h. Wells were washed five times in washing
buffer and 50Ltl of Sigma 104 phosphatase substrate (Sigma,
Poole), diluted to 1 mgml ' in substrate buffer, was added.
The absorbence of each well was read after 45 min at 405 nm
in a Titertek multiscan.
Results
Disaggregation ofsolid tumours
Dissaggregation of solid tumours yields a mixed population
of cells including red blood cells, lymphocytes, stromal cells,
macrophages and endothelial cells. The percentage of
epithelial cells, as measured by staining of cytokeratin with
monoclonal antibody Cam 5.2, was only 22 ± 13% (range
10-80). However, following forward angle light scatter
gating to selectively analyse cells in the malignant cell size
range 79 ± 4% (range 69-86) of the cells analysed were
epithelial. Furthermore the variation between tumours was
considerably reduced.
The percentage of lymphocytes, as measured by staining
with the monoclonal antibody F1O-89-4, in the total
nucleated population was 74 16% (range 40-90). This was
considerably reduced to 5.5 ± 5% (range 1-20) following
FACS IV gating for malignant cell size. The percentage of
stromal cells in the population of cells analysed in the malig-
nant size range was 3.5 ± 3% (range 1-13).
The percentage of non-epithelial cells in the forward light
scatter gate was low, and it did not vary considerably
between tumours (21 + 4%). If the monoclonal antibodies
cross-reacted with these cells it may have contributed to the
intensity of staining. However, only monoclonal antibody
791T/36 stained any of the normal cells found within the
tumours. This antibody stains stromal cells but no distinct
peak of fluorescence could be detected on careful analysis of
the fluorescence profiles, suggesting that these cells do not
affect the mean intensity of staining.ENHANCED BINDING OF COMBINATIONS OF ANTIBODIES TO TUMOURS
Antigen expression on tumour cells
Expression of CEA and the Y hapten on colorectal tumours
have previously been shown by immunoperoxidase staining
of cryopreserved tissue. However, there are advantages in
analysing tumour cell suspensions by indirect
immunofluorescence and flow cytometric analysis. A large
proportion of the tumour ( -5 g of tissue was disaggregated,
a minimum of 104 epithelial cells were processed per
antibody) was analysed, which allows accurate quantification
of the mean antibody binding level per cell for each individ-
ual tumour and the percentage of cells within a tumour
which bind each monoclonal antibody.
Analysis of the binding of a panel of monoclonal
antibodies, recognising tumour associated antigens, to a
series of disaggregated colorectal tumours illustrates the
inter-tumour variation in intensity of staining (Figure 1) and
the intra-tumour variation in the percentage of cells express-
ing the relevant antigens (Figure 2).
All of the monoclonal antibodies recognising tumour
associated antigens stained the majority of tumours with a
moderate intensity (MLFs of 122-1,000). However, mono-
clonal antibody 161 stained the most tumours (36%) with
strong intensity (MLF> 1,000), monoclonal antibodies C14
and 228 both stained 26% of tumours strongly whereas
791T/36 failed to stain any tumours strongly. The mono-
clonal antibodies recognising stromal cells and the lym-
phocytes both stained cells in the malignant cell size range
weakly (MLF> 122). In contrast the monoclonal antibody,
Cam5.2, recognising epithelial cells bound 58% of the
tumours moderately and 42% strongly.
None of the monoclonal antibodies stained all the tumour
cells within every lesion. Indeed the best, 161, stained a mean
of 59% of cells within a tumour, whereas the monoclonal
antibody Cam5.2, which recognised epithelial cells, stained a
mean of 74% of the cells per tumour. Furthermore, none of
the monoclonal antibodies stained cells within all of the
tumours, 791T/36 stained cells within 64% of the tumours,
C14 stained 83%, 228 stained 82% and 161 stained 90%.
Any single monoclonal antibody therefore failed to react
with between 10 and 36% of the colorectal tumours.
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Figure 2 Percentage of cells within a tumour recognised by a
series of monoclonal antibodies. Disaggregated colorectal
tumours are stained by indirect immunofluorescence and analysed
by flow cytometry. Each point refers to an individual tumour.
Immunophenotypes
Immunophenotypes of colorectal tumours were analysed to
determine if an appropriate combination of monoclonal
antibodies could stain all of the tumours (Figure 3). Cell
suspensions from each tumour were stained separately with
each of the monoclonal antibodies. If a population stained
significantly with a monoclonal antibody (see Materials and
methods) then the tumour was assigned to the relevant
immunophenotype. If a tumour only stained with C14 then it
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Monoclonal antibodies
Figure 1 Binding of monoclonal antibodies to freshly disagg-
regated colorectal tumour cells as stained by indirect
immunofluorescence and analysed by flow cytometry. Each point
refers to an individual tumour.
161
C14 228
C14
791T/36
161
C14 X3X( 228
Figure 3 Colorectal tumour immunophenotypes. Cell suspen-
sions from each tumour were stained separately with each of the
monoclonal antibodies. If a population stained significantly with
a monoclonal antibody (see Materials and methods) then the
tumour was assigned to the relevant immunophenotype. If a
tumour only stained with C14 then that is its phenotype. How-
ever, if some cells stained with C14 and/or 161 then it would have
a C14, 161 phenotype. The figures inside the circles refer to the
percentage of 50 tumours in which some of their cells stained
with the designated antibodies.
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was designated as a C14 phenotype (i.e. 6% of the tumours).
However, if some of the tumour cells stained with C14
and/or 161 then it would have a C14, 161 phenotype (i.e. 6%
of the tumours). Ten per cent of the tumours expressed only
a single epitope and therefore the monoclonal antibodies
reacting with these epitopes must be included in any com-
bination if all tumours are to be recognised. Table II
computes the potential effectiveness of various optimum
combinations of all four monoclonal antibodies, 161, 228,
C14 and 791T/36, in a series of 50 colorectal tumours. The
best combination would consist of all four monoclonal
antibodies as this would recognise all of the colorectal
tumours, 60% binding all four, 18% any three, 12% any two
and 10% binding a single monoclonal antibody. However, a
combination excluding antibody 161 which cross-reacts with
NCA found on normal granulocytes would still be effective
against 98% of the tumours, 60% reacting with all three
monoclonal antibodies and 80% with any two. A combina-
tion of C14 and 228 would also stain 98% of the tumours;
70% of these would react with both monoclonal antibodies.
Binding to extranuclear membranes
Binding of a panel of four monoclonal antibodies, 791T/36,
C14, 228 and 161, to a panel of 12 tumour and autologous
normal membrane preparations were assessed. Significant
binding to normal colon membranes was only observed for
monoclonal antibody 161 and it has therefore been excluded
from these studies. Results of the binding of the other three
monoclonal antibodies singly and in combinations are shown
in Table III.
C14 monoclonal antibody bound with the strongest inten-
sity when compared to 791T/36 (P<0.01) or to 288
(P<0.05). However, a combination of C14 and 228 stained
significantly stronger than either C14 (P<0.01) or 228
(P<0.01). Furthermore the combination stained all of the
membranes. The addition of 791T/36 failed to significantly
increase the intensity of staining seen with C14 and/or 228.
Ofparticular interest was the tumour (T8) which only stained
weakly with the monoclonal antibody C14 and failed to stain
significantly above background with the monoclonal
Table II Optimum combinations of monoclonal antibodies which
react with colorectal tumours
Monoclonal % oftumours binding
antibodies any one antibody
C14 88
791T/36 70
228 80
161 90
C14 and 228 98 (70)-
C14 and 791T/36 92 (66)-
791T/36 and 228 86 (64)a
791T/36, 228 and C14 98 (80)a (60)b
791T/36, 228, C14 and 791T/36 100(90)- (78)b (60)C
a% oftumours which bind two antibodies. b% oftumours which bind
three antibodies. c% of tumours which bind four antibodies.
antibodies 228 and 791T/36. All the combinations bound
significantly but a combination of 228 and C14 bound 2.2
times more strongly than C14 alone. None of the combina-
tions significantly stained autologous normal membranes.
Discussion
Murine monoclonal antibodies directed against tumour
associated antigens are potentially useful for both tumour
diagnosis and therapy. However, previous studies have
shown qualitative differences in tumour associated antigen
expression between tumours (Durrant et al., 1986; Ballantyne
et al., 1986; Spremulli et al., 1983) and within a tumour
(Durrant et al., 1986b; Petricciani, 1982). Furthermore, the
level of antigen expression on individual cells within a
tumour varies enormously (Durrant et al., 1986b). This may
lead to failure to detect all tumour lesions and/or escape of
tumour cells within a tumour during therapy with a single
monoclonal antibody. The purpose of this study was to
establish if monoclonal antibodies, recognising colorectal
tumour associated antigens, could reduce inter and intra-
tumour heterogeneity when used in combinations rather than
individually. A qualitative flow cytometric assay which
rapidly processes large numbers of tumour cells (104
epithelial cells) has been developed (Durrant et al., 1986a)
and was chosen as the most suitable analysis for this study.
Inter-tumour heterogeneity was completely abrogated by
using a combination of the monoclonal antibodies, 791T/36,
228, C14 and 161, as all 50 tumours studied were stained by
one or more of these monoclonal antibodies. This combina-
tion excluding the monoclonal antibody 161 which recognises
CEA but cross-reacts with NCA and therefore stains normal
colon and granulocytes, recognised 49 of the 50 tumours
analysed. Ninety-eight per cent of these lesions would
therefore be recognised by this simple combination of three
antibodies. Similarly, although both 228 and C14 recognised
92% of the tumour extranuclear membranes, a combination
of both antibodies bound significantly to 100% of the mem-
branes.
Monoclonal antibodies 791T/36 and 228 have been used
for diagnostic imaging of colorectal cancer (Armitage et al.,
1983; Pimm et al., 1986). As C14 is an IgM antibody its
molecular size precludes efficient localisation in tumour.
However, these studies clearly show that the Y hapten is an
extremely important colorectal tumour associated antigen
and that an IgG variant of C14 may be clinically valuable.
To reduce non-specific toxicity the optimal drug delivery
system requires cleavage of the drug after the conjugate has
bound to the tumour associated antigen and internalised. The
majority of large molecules are transported by constitutive
pinocytosis (Besterman & Low, 1983). Both 791T/36 and 228
monoclonal antibodies enter tumour cells by this route
(Garnett et al., 1986b; Byers et al., 1988). There is no reason
to assume C14 antibody will not be internalised by a similar
mechanism. The antigen density per cell is very important as
it will determine the number of molecules of conjugate inter-
nalised. An MLF of 1,000 approximately corresponds to
Table III Binding of monoclonal antibodies singly or in combinations to the extranuclear membrane preparations of colorectal tumours
Non-parametric, paired
Binding to extranuclear membranes as measured by ELISA (OD x 10) Wilcoxon rank test
Monoclonal
Antibody T T T T T T T T T T T T C14 791T/36 228
C14 697 1304 668 1000 460 781 286 140 274 1269 191 1211 n.a. P<0.01 P<0.05
791T/36 114 239 251 290 280 398 152 21 46 114 223 246 P<0.01 n.a. P<0.01
228 186 901 561 1008 420 644 490 108 175 327 2021 646 P<0.05 P<0.01 n.a.
C14 + 791T/36 616 974 698 1007 590 873 314 254 46 1050 229 1197 n.s. P<0.01 n.a.
791T/36 + 228 244 1019 576 1077 470 649 417 205 286 244 2084 647 n.a. P<0.01 n.s.
228 + C14 634 1584 923 1273 610 1046 611 313 253 1460 2269 1431 P<0.01 n.a. P<0.01
791T/36 + C14 + 228 732 1554 910 1273 520 1103 544 279 286 1158 2152 1536 P<0.01 P<0.01 P<0.01
nMse Ig 104 241 262 287 260 126 80 104 103 114 181 108 P<0.01 P<0.01 P<0.01
Meanopticaldensityofquadruplicatewellswasreadat405nm. Thestandarderrorofthemeanwaslessthan 5% foralltheseresults. Normalmouse
immunoglobulin wasincluded as anegative control. n.a., notapplicable; n.s., not significant. The strongest bindingforeach tumour is shown in bold.ENHANCED BINDING OF COMBINATIONS OF ANTIBODIES TO TUMOURS 859
50,000 molecules of antibody bound per cell assuming that
an average of two molecules of FITC conjugated mouse Ig
binds to each monoclonal antibody molecule. The
fluorescence to protein ratio of the anti-mouse sera was 2.3
and under the analysis conditions used there are 2,200 FITC
molecules per channel. Any monoclonal antibody substituted
with two molecules of drug which bound with an MLF of
1,000 would only have to internalise antigen conjugate com-
plex once in order to internalise one million molecules of
drug. This is the number of molecules of methotrexate that
had to be internalised to kill 50% of the colorectal cancer
cells in an in vitro cytotoxicity assay (Durrant & Garnett,
unpublished results). Monoclonal antibody 161 stained 36%
of the tumours with this intensity whereas monoclonal
antibodies 228 and C14 both stained 26%. If a higher
percentage of tumours are to be efficiently killed by drugs
such as methotrexate, both repeated exposure and continuous
internalisations would be necessary. Alternatively, drugs
could be attached to combinations of antibodies which in-
crease the intensity of binding, more cytotoxic agents such as
ricin toxin (Casellas et al., 1984) could be conjugated to
antibody or more molecules of a drug could be attached via
a carrier to each antibody molecule (Garnett & Baldwin,
1986). The disadvantage of the latter two methods is that if
the tumour associated antigen is only expressed weakly on
normal cells sufficient drug will accumulate to cause cytotox-
icity.
The intensity of staining tumour membranes was increased
without significant binding to autologous normal colon mem-
branes using combinations of either 228 and C14 or of 228,
C14 and 791T/36 when compared to binding of each individ-
ual monoclonal antibody. In fact, one tumour which failed to
bind significantly to any single monoclonal antibody stained
significantly with a combination of 228 and C14. Similar in
vitro studies in our laboratory have shown that two high
affinity anti-CEA antibodies, 198 and B14/B8, potentiated
the binding of 228 monoclonal antibody to the surface of
MKN45 cells by increasing the dwell time of the cell bound
antibody. This in turn led to increased endocytosis of the
antibody and when 228 was linked to ricin A chain produced
enhanced cytotoxicity (Byers et al., 1988). As the spectrum of
antigen expression is different on normal tissues these effects
may not be seen on healthy tissue and therefore combina-
tions of monoclonal antibodies may increase the tumour to
normal binding ratios. The only normal tissue which more
than one of the antibodies cross-react with by immunohis-
tology is gastrointestinal epithelium. No significant binding
to normal colon membranes of any of the monoclonal
antibodies, either alone or in combinations, was detected,
probably because CEA and the antigen bearing the Y hapten
are exclusively expressed as secretory products and not mem-
brane antigens in normal tissue. Viable epithelial cells from
normal colon are difficult to prepare, but limited flow
cytometric tests with cells derived from non-tumour tissue in
resected colon tumour specimens confirm this low level of
reactivity. Thus 791T/36 was unreactive in 3/3 tests; anti-
CEA antibodies gave a MLF of 18.4 (five tests) and C14 an
MLF of 71.9 (three tests) above a background MLF of 48.1.
Further studies using FITC labelled monoclonal antibodies
to tumour associated antigens, and biotin labelled anti-
cytokeratin antibodies and avidin phycoerythrin to identify
epithelial cells will allow direct measurements of any increase
in the intensity of staining and the percentage of cells recog-
nised using combinations of antibodies. Krizan et al. (1985)
showed that both the relative fluorescence and the percentage
of cells recognised was increased when suboptimal doses of
three monoclonal antibodies were added to cells rather than
saturating concentrations of each monoclonal antibody alone
or combined. Perhaps the total dose of monoclonal antibody
can be reduced by using combinations.
Ceriani et al. (1987) demonstrated that a combination of
antibodies recognising different epitopes on the same antigen
could increase the therapeutic effect against a relevant human
xenograft, but not against an antigen negative xenograft,
when compared to single antibody studies.
If combinations of monoclonal antibodies were used
clinically these studies predict that all lesions could be recog-
nised and the intensity of staining would be increased but
without significant binding to normal colon. This should
greatly increase the number of tumours detected by
radiolabelled antibodies and increase the therapeutic
effectiveness of monoclonal antibody drug conjugates.
L.G.D., R.A.R., K.C.B., R.A.M. and R.W.B. are supported by the
Cancer Research Campaign, UK. The skilful technical assistance of
J. Wright and 0. Roberts is gratefully acknowledged.
References
ABE, K., HAKOMORI, S. & OHABIB, S. (1986). Differential expression
of difucosyl Type 2 chain (le) defined by monoclonal antibody
AH6 in different locations of colonic epithelial, various his-
tological types of colonic polyps and adenocarcinomas. Cancer
Res., 46, 2639.
ARMITAGE, N.C., PERKINS, A.C., PIMM, M.V., FARRANDS, P.A.,
BALDWIN, R.W. & HARDCASTLE, J.D. (1983). The localisation of
anti-tumour monoclonal antibody (79IT/36) in gastrointestinal
tumours. Br. J. Surg., 31, 407.
BALLANTYNE, K.C., DURRANT, L.G., ARMITAGE, N.C., ROBINS,
R.A., BALDWIN, R.W. & HARDCASTLE, J.D. (1986). Binding of a
panel of monoclonal antibodies to primary and metastatic col-
orectal cancer. Br. J. Cancer, 54, 191.
BESTERMAN, J.M. & LOW, R.B. (1983). Endocytosis: a review of
mechanisms and plasma membrane dynamics. Biochem. J., 210, 1.
BRATTAIN, M.G., FINE, W.D., KHATED, F.M., THOMPSON, J. &
BRATTAIN, D.E. (1981). Heterogeneity of malignant cells from a
human colonic carcinoma. Cancer Res., 41, 1751.
BROWN, A., FEIZI, T., GOOI, H.C., EMBLETON, M.J., PICARD, J.K. &
BALDWIN, R.W. (1983). A monoclonal antibody against human
colonic adenoma recognizes difucosylated type-2 blood group
chains. Biosci. Rep., 3, 163.
BROWN, A., ELLIS, I.O., EMBLETON, M.J., BALDWIN, R.W.,
TURNER, D.B. & HARDCASTLE, J.D. (1984). Immunohis-
tochemical localization of Y hapten and the structurally related
H type 2 blood group antigen on large bowel tumours and
normal adult tissues. Int. J. Cancer, 33, 727.
BYERS, V.S., PAWLUCZYK, I., BERRY, N. & 5 others (1988). Poten-
tiation of anti-carcinoembryonic antigen immunotoxin cytotox-
icity by monoclonal antibodies reacting with co-expressing car-
cinoembryonic antigen epitopes. J. Immunol., 140, 4050.
BYERS, V.S., RODVIEN, R., GRANT, K. & 4 others (1989). Phase I
study of monoclonal antibody 791T/36-ricin A chain
immunotoxin in metastatic colon cancer. Cancer Res. (in the
press).
CASELLAS, P., BOURRIE, B.J.P., GROS, P. & JANSEN, F.K. (1984).
Kinetics ofcytotoxicity induced by immunotoxins. J. Biol. Chem.,
259, 9358.
CERIANI, R.L. BLANK, E.W. & PETERSON, J.A. (1987). Experimental
immunotherapy of human breast carcinomas implanted in nude
mice with a mixture of monoclonal antibodies against human
milk fat globule components. Cancer Res., 47, 532.
DALCHAU, R., KIRLEY, J. & FABRE, S.W. (1980). Monoclonal
antibody to a human leucocyte specific membrane glycoprotein
probably homologous to the leucocyte common antigen of the
rat. Eur. J. Immunol., 10, 737.
DEXTER, D.L., SPREMULLI, E.N., FLIGIEL, Z. & 4 others (1981).
Heterogeneity of cancer cells from a single human colon car-
cinoma. Am. J. Med., 71, 949.
DURRANT, L.G., ROBINS, R.A., ARMITAGE, N.C., BROWN, A.,
BALDWIN, R.W. & HARDCASTLE, J.D. (1986a). Association of
antigen expression and DNA ploidy in human colorectal
tumours. Cancer Res., 46, 3543.
DURRANT, L.G., ROBINS, R.A., PIMM, M.V. & 4 others (1986b).
Antigenicity of newly established colorectal cell lines. Br. J.
Cancer, 53, 37.
EMBLETON, M.J., GUNN, B., BYERS, V.S. & BALDWIN, R.W. (1981).
Antitumour reactions of monoclonal antibody against a human
osteogenic sarcoma cell line. Br. J. Cancer, 43, 582.860 L.G. DURRANT et al.
ERNST, C.S., SHEN, J.-W., LITWIN, S., HERLYN, M., KOPROWSKI, H,
& SEARS, H.F. (1986). Multiparameter evaluation of the expres-
sion in situ of normal and tumor-associated antigens in human
colorectal carcinoma. J. Natl Cancer Inst., 77, 387.
FARRANDS, P.A., PERKINS, A.C., PIMM, M.V., HARDY, J.G., BALD-
WIN, R.W. & HARDCASTLE, J.D. (1982). Radioimmunodetection
of human colorectal cancers using an anti-tumour monoclonal
antibody. Lancet, ii, 397.
GARNETT, M.C. & BALDWIN, R.W. (1986a). An improved synthesis
of a methotrexate-albumin-791T/36 monoclonal antibody con-
jugate cytotoxic to osteogenic sarcoma cell lines. Cancer Res., 46,
2407.
GARNETT, M.C. & BALDWIN, R.W. (1986b). Endocytosis of a
monoclonal antibody recognising a cell surface glycoprotein
antigen visualised using fluorescent conjugates. Eur. J. Cell Biol.,
41, 214.
HERLYN, M., STEPLEWSKI, Z., HERLYN, D. & KOPROWSKI, H.
(1979). Colorectal carcinoma specific antigen: detection by means
of monoclonal antibodies. Proc. Natl Acad. Sci. USA 76, 1438.
KRIZAN, Z., MURRAY, S.L., HERSH, E.M. & 4 others (1985).
Increased labeling of human melanoma cells in vitro using com-
binations of monoclonal antibodies recognising separate cell
surface antigenic determinants. Cancer Res., 45, 4904.
LINDHOLM, L., HOLMGREN, J., SVENNERHOLM, L. & 5 others
(1983). Monoclonal antibodies against gastrointestinal tumour-
associated antigens isolated as monosialo gangliosides. Int. Arch.
Allergy Appi. Immunol., 71, 178.
LLOYD, K.O., LARSON, G., STROMBERG, N., THURIN, J. & KARL-
SSON, K.A. (1983). Mouse monoclonal antibody F-3 recognises
difucosyl type-2 blood group structure. Immunogenetics, 17, 537.
MCKENZIE, J.K.L. & FABRE, J.W. (1981). Human Thy-i unusual
localisation and possible functional significance in lymphoid tis-
sues. J. Immunol., 126, 843.
MAKIN, C.A., BOBROW, L.G. & BODMER, W.F. (1984). Monoclonal
antibody to cytokeratin for use in routine histopathology. J. Clin.
Pathol., 37, 975.
PETRICCIANI, J.C., SMITH, P., EARLEY, E.M., LEVENBOOK, I. &
NOGUCHI, P. (1982). Characteristics of seven clones of WiDr
human colon adenocarcinoma cell line. In Vitro, 18, 492.
PIMM, M.V., PERKINS, A.C., BALLANTYNE, K.C. & 6 others (1986).
Experimental and clinical imaging of gastrointestinal carcinomas
with "'In-labelled anti-CEA monoclonal antibodies. Br. J.
Cancer, 54, 188.
PRICE, M.R., CAMPBELL, D.G. & BALDWIN, R.W. (1983a).
Identification of an anti-human osteogenic sarcoma monoclonal-
antibody-defined antigen on mitogen-stimulated peripheral blood
mononuclear cells. Scand. J. Immunol., 18, 411.
PRICE, M.R., CAMPBELL, D.G., ROBINS, R.A. & BALDWIN, R.W.
(1983b). Characteristics of a cell surface antigen defined by an
anti-human osteogenic sarcoma monoclonal antibody. Eur. J.
Cancer Clin. Oncol., 19, 81.
PRICE, M.R., EDWARDS, S., JACOBS, E., PAWLUCZYK, I.Z.A.,
BYERS, V.S. & BALDWIN, R.W. (1987). Mapping of monoclonal
antibody-defined epitopes associated with carcinoembyronic
antigen, CEA. Cancer Immunol. Immunother., 25, 10.
SPREMULLI, E.N., SCOTT, C., CAMPBELL, D.E. & 4 others (1983).
Characteristics of two metastatic subpopulations originating from
a single human colon carcinoma. Cancer Res., 43, 3828.
STEPLEWSKI, Z & KOPROWSKI, H. (1982). Monoclonal antibody
development in the study of colorectal carcinoma-associated
antigens. In Methods of Cancer Research 20, Busch, H. &
Yeoman, L.C. (eds) p. 285. Academic Press: London.